PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).

Mary-Ellen Taplin,Martin E. Gleave,Christopher H Evans,Eleni Efstathiou,Philip W. Kantoff,Ashley E. Ross,Neal D. Shore,Alberto Briganti,Boris Hadaschik,Axel Heidenreich,Oliver Brendan Rooney,Shaozhou Ken Tian,Lisa Wetherhold,Weichun Xu,Shinta Cheng,Sabine Brookman-May,Angela Lopez-Gitlitz,Adam S. Kibel

PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).

2019

Mary-Ellen Taplin
Martin E. Gleave
Christopher H Evans
Eleni Efstathiou
Philip W. Kantoff
Ashley E. Ross
Neal D. Shore
Alberto Briganti
Boris Hadaschik
Axel Heidenreich
Oliver Brendan Rooney
Shaozhou Ken Tian
Lisa Wetherhold
Weichun Xu
Shinta Cheng
Sabine Brookman-May
Angela Lopez-Gitlitz
Adam S. Kibel

TPS5100Background: Patients (pts) with localized high-risk PC experience disease progression rates of approximately 50% after RP (Kane et al. J Urol. 2007). With the approval of next-generation and...

Keywords:

Proteus
Placebo
Prostate cancer
Prostatectomy
Apalutamide
Urology
Pathology
Androgen deprivation therapy
Medicine
locally advanced
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations